A detailed history of Pax Financial Group, LLC transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Pax Financial Group, LLC holds 9,947 shares of NBIX stock, worth $1.37 Million. This represents 0.29% of its overall portfolio holdings.

Number of Shares
9,947
Previous 10,379 4.16%
Holding current value
$1.37 Million
Previous $1.37 Million 0.29%
% of portfolio
0.29%
Previous 0.29%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 13, 2024

SELL
$130.4 - $143.74 $56,332 - $62,095
-432 Reduced 4.16%
9,947 $1.37 Million
Q4 2023

Feb 12, 2024

SELL
$106.07 - $132.76 $127,496 - $159,577
-1,202 Reduced 10.38%
10,379 $1.37 Million
Q3 2023

Nov 13, 2023

SELL
$94.02 - $117.1 $553,871 - $689,836
-5,891 Reduced 33.72%
11,581 $1.3 Million
Q2 2023

Jul 18, 2023

BUY
$89.53 - $104.87 $108,958 - $127,626
1,217 Added 7.49%
17,472 $1.65 Million
Q1 2023

May 11, 2023

BUY
$94.11 - $123.02 $1.53 Million - $2 Million
16,255 New
16,255 $1.65 Million

Others Institutions Holding NBIX

About NEUROCRINE BIOSCIENCES INC


  • Ticker NBIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 95,639,296
  • Market Cap $13.1B
  • Description
  • Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...
More about NBIX
Track This Portfolio

Track Pax Financial Group, LLC Portfolio

Follow Pax Financial Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pax Financial Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pax Financial Group, LLC with notifications on news.